Asher Biotherapeutics joins search for a better IL-2 sans the toxicities
Can IL-2 therapies — which can be powerful against cancer but infamous for their toxic side effects — be made inherently more specific? For Asher Biotherapeutics, that’s the $55 million question.
Ivana Djuretic and Andy Yeung left their jobs in cancer immunology and protein engineering at Pfizer in 2019 to start Asher with the idea that they could improve the efficacy of immunotherapies. More specifically, they wanted to know if restricting the activity of a cytokine to only the cells that matter would counterintuitively result in better therapeutics.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
